Ozempic market was valued at $24.7 billion in 2024 and is anticipated to reach $66.5 billion by 2035, growing at a CAGR of 9.4% during the forecast period (2025-2035). The market growth is driven by an increase in demand for effective treatment options for type 2 diabetes and obesity, and heightened awareness regarding preventative health care, which are driving market growth.
Browse the full report description of “Ozempic Market Size, Share & Trends Analysis Report by Indication (Type-2 Diabetes, Obesity / Weight Management, Cardiovascular-Risk-Reduction (anticipated), and Other Emerging Uses), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online / Mail-Order Pharmacies, and Tele-health Platforms), Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/ozempic-market
The increasing prevalence of inactive lifestyles and related chronic diseases is driving sustained demand for semaglutide (Ozempic) therapies. Additionally, improvements in drug delivery systems and patient-centered care are impacting the treatment landscape.
Ozempic Improvements Increase Efficacy, Safety, and Accessibility
- Drug formulation and delivery continue to improve, enhancing patient adherence, as the longer dosing intervals from weekly doses do decrease potentially negative impacts of the treatment when compared to dosing daily.
- Digital health platforms, wearable devices, and AI-based monitoring tools allow for personalized treatment plans, support tracking adherence, and supply patient health information during the use of Ozempic.
- The expanded list of acceptable indications for patients approved for weight management in individuals without diabetes offers the potential for an expanded market.
- Increased investment in clinical trials and real-world evidence supports the cardiovascular and metabolic benefits of semaglutide in the long term, resulting in greater physician reassurance in prescribing Ozempic.
Key Market Players and Strategic Initiatives
Novo Nordisk A/S dominates the ozempic market; companies in several countries are investing more into research, production, and distribution partnerships to secure a position in the GLP-1 receptor agonists market. To build their positions, competitor companies such as Sumitomo Pharma Co., Ltd., Novo Nordisk A/S, GEROPHARM LLC, Biocon Ltd., Eli Lilly and Co. are developing pipeline product advancements and companion companies that can provide access and medical success.
Novo Nordisk A/S is expanding its semaglutide portfolio and has already contemplated potentially developing next-generation oral formulations to enhance convenience and patient acceptance of the medication. Eli Lilly and Company remains committed to advancing tirzepatide, a dual GIP/GLP-1 receptor agonist, which may change the competitive landscape. Additionally, digital health providers are beginning to partner to provide more comprehensive solutions for diabetes and obesity through integrated treatment and monitoring in the management of these chronic diseases.
Recent Developments
- In May 2025, Sumitomo Pharma Co., Ltd. announced that Sumitomo Pharma and Novo Nordisk Pharma Ltd. have entered into a co-promotion agreement in Japan for Ozempic Subcutaneous Injection 2 mg, a once-weekly subcutaneous GLP-1 receptor agonist indicated for the treatment of type 2 diabetes. Through this agreement between Novo Nordisk Pharma and Sumitomo Pharma, both having wide experience and strength in promoting products in diabetes care, we aim to make Ozempic accessible to more people with diabetes who require this treatment.
- In January 2025, Novo Nordisk announced that the US FDA had approved Ozempic to reduce the risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death owing to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD). This approval, along with its existing indications for adults with type 2 diabetes to improve glycemic control and to reduce the risk of major cardiovascular events in adults with known heart disease, establishes Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg as the most broadly indicated glucagon-like peptide-1 receptor agonist (GLP-1 RA) in its class.
Market Coverage
- The market number available for – 2024-2035
- Base year- 2024
- Forecast period- 2025-2035
- Segment Covered-
- By Indication
- By Distribution Channel
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape - Sumitomo Pharma Co., Ltd., Novo Nordisk A/S, GEROPHARM LLC, Biocon Ltd., Eli Lilly and Co., and others.
Key questions addressed by the report.
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Ozempic Market Report Segment
By Indication
- Type-2 Diabetes
- Obesity / Weight Management
- Cardiovascular-Risk-Reduction (anticipated)
- Other Emerging Uses
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online / Mail-Order Pharmacies
- Tele-health Platforms
Global Ozempic Market Report Segment by Region
North America
Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia and New Zealand
- ASEAN Economies
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/ozempic-market